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Abstract
Background: Guideline recommendations for chronic obstructive pulmonary disease (COPD) are based on the results of
large pharmaceutically-sponsored COPD studies (LPCS). There is a paucity of data on disease characteristics at the primary
care level, while the majority of COPD patients are treated in primary care.
Objective: We aimed to evaluate the external validity of six LPCS (ISOLDE, TRISTAN, TORCH, UPLIFT, ECLIPSE, POET-COPD)
on which current guidelines are based, in relation to primary care COPD patients, in order to inform future clinical practice
guidelines and trials.
Methods: Baseline data of seven primary care databases (n = 3508) from Europe were compared to baseline data of the
LPCS. In addition, we examined the proportion of primary care patients eligible to participate in the LPCS, based on
inclusion criteria.
Results: Overall, patients included in the LPCS were younger (mean difference (MD)-2.4; p = 0.03), predominantly male (MD
12.4; p = 0.1) with worse lung function (FEV1% MD -16.4; p,0.01) and worse quality of life scores (SGRQ MD 15.8; p = 0.01).
There were large differences in GOLD stage distribution compared to primary care patients. Mean exacerbation rates were
higher in LPCS, with an overrepresentation of patients with$1 and$2 exacerbations, although results were not statistically
significant. Our findings add to the literature, as we revealed hitherto unknown GOLD I exacerbation characteristics,
showing 34% of mild patients had $1 exacerbations per year and 12% had $2 exacerbations per year. The proportion of
primary care patients eligible for inclusion in LPCS ranged from 17% (TRISTAN) to 42% (ECLIPSE, UPLIFT).
Conclusion: Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality
of life and exacerbations. More research is needed to determine the effect of pharmacological treatment in mild to
moderate patients. We encourage future guideline makers to involve primary care populations in their recommendations.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
most complex diseases seen by respiratory physicians and general
practitioners (GPs). Patients suffer from fluctuating episodes of
exacerbations and airway symptoms which are difficult to control
and may not sufficiently respond to inhalation therapy.
In the last 30 years, more than 50 (inter)national guidelines on
the management of COPD have been published worldwide [1].
However, despite international dissemination and intensive
promotion, guidelines are not widely adopted in daily practice
[2]. Recently, two surveys revealed that COPD management by
GPs was well below guideline-recommended levels, with many
GPs having very limited knowledge of COPD and its management
[3,4]. Furthermore, about 25% of the GPs reported to be
unfamiliar with GOLD and one-third with ATS/ERS guidelines
[4]. Overall, non-guideline-informed management was a conse-
quence of no availability, no confidence in gauging pharmacologic
response, or because the GPs considered the guidelines too long,
not relevant, or expressed no agreement with guidelines [3,4].
Recommendations in guidelines are usually based on the
strongest category of evidence: (meta-analyses of) randomized
clinical trials (RCTs). These RCTs, particularly in medication
studies, included large and selected COPD populations to ensure
that the effect of the studied treatment is not concealed by
confounding factors [5]. Furthermore, mild COPD patients are
often neglected in these trials, as inclusion criteria are restricted to
values of predicted forced-expiratory volume in 1 second (FEV1%
predicted) below 70%. Moreover, selected patients are generally
those with sufficient motivation and time to participate in a trial,
and most likely to comply with medication and regular appoint-
ments. It is questionable whether the results of such RCTs can be
extrapolated to all patients with COPD [5,6]. However, reliable
judgments about the external validity of RCTs are essential if
treatments are to be used correctly in as many patients as possible
in routine clinical practice [7]. Recent GOLD guidelines
acknowledge this limited generalizability in COPD studies and
state some considerations related to the results of these trials [8].
However, there still remains a paucity of data in the literature
regarding COPD patient characteristics at the primary care level,
and therefore it still remains unknown if there is overlap in disease
characteristics of populations included in large RCT’s compared
to the population seen in primary care. For example, exacerbation
prevalence data in mild COPD patients remains still unknown,
and exacerbation prevalence data in the other GOLD stages are
solely based on the results of large trials [8].
To this end, the aim of this study was to evaluate the external
validity of six large pharmaceutically sponsored COPD studies [9–
14]. We aimed to provide insight into disease characteristics of
COPD patients in primary care, in order to inform future
guidelines and trialists. A secondary aim was to describe the




UNLOCK patients: Seven primary care databases from the
UK, the Netherlands, Sweden and Greece were combined to
create an extensive dataset of primary care COPD patients in the
UNLOCK study [15]. All individual datasets included baseline
data collected as part of on-going real-life cohort studies or
pragmatic clinical trials in primary care. Inclusion criteria
consisted of spirometrically validated COPD patients according
to GOLD guidelines [8]; all studies applied few/limited or no
exclusion criteria. Additional information on the methodology of
the relevant studies is reported in the references. The UK dataset
was a cohort study including 375 COPD diagnosed patients
gathered to derive and validate a multicomponent assessment tool
of COPD severity (the DOSE index); exclusion criteria consisted
of serious co-morbidity affecting the patient’s ability to take part or
to perform spirometry [16]. The Netherlands had four primary
care datasets: two studies [one controlled clinical trial, Bocholtz
study; n= 154 [17] and one cluster RCT, RECODE trial
(Netherlands Trial Register (NTR) number 2268); n = 1086
[18]] aimed to evaluate the long-term effects of a multidisciplinary
disease management program on quality of life. Both these studies
included COPD patients and had limited exclusion criteria
(terminal disease, immobility, substance abuse and inability to fill
in questionnaires). The third dataset included 51 COPD
diagnosed patients with a smoking history of . 10 years enrolled
in a pilot for a RCT (The MARCH study; NTR number 2643)
assessing the effect of health status guided care compared to
GOLD guideline guided care in the primary care setting. [19]
Exclusion criteria were patients with a myocardial infarction , 3
months ago, history of asthma/allergic rhinitis before age 40 years,
oxygen use, dementia, or unstable or life-threatening comorbid
condition. The fourth dataset comprised 1736 patients who were
diagnosed and followed-up by the Asthma/COPD service in the
Netherlands. This consultation service (including medical history,
health status, lung function test and inhalation technique
evaluation) is used by GPs for patients with (a suspicion of)
asthma or COPD. For this latter study, only COPD patients were
included and no exclusion criteria were applied. The Greek cohort
study was designed to explore issues on quality of life, physical
activity and dyspnea and included 109 primary care COPD
patients with a smoking history of . 10 years; exclusion criteria
were history of asthma, unstable cardiovascular disease, or any
other respiratory disease other than COPD [20]. The dataset from
Sweden included a cohort study (PRAXIS-study) of 775 primary
care COPD patients aged 45–75 years, randomly selected from
the medical records of 56 primary healthcare centres; there were
no exclusion criteria [21,22].
Ethical approval: The UK dataset was obtained with the aim
to collect anonymised data on COPD patients. The South West
Multicentre Research Ethics Committee confirmed that as a
service evaluation, formal research ethics approval was not
required for the audit. Patients were informed about the study
and confidentiality issues. Patient consent was obtained to collect
and analyse the data using an electronic consent form approved by
the NHS information security and registration authority [16]. In
the Dutch Bocholtz clinical trial, the regional Medical Ethics
Committee of the Atrium Medical Centre, Heerlen, approved the
study protocol. All patients gave written informed consent [17].
The Medical Ethics Committee of the Leiden University Medical
Centre approved the Dutch RECODE trial, and all patients gave
written informed consent [18]. Data from the Bocholtz and
RECODE study is hosted at the department of Public Health and
Primary Care at the Leiden University Medical Centre. The
MARCH study was approved by the Medical Ethical Committee
of the University Medical Centre Groningen, and data is hosted at
the University Medical Centre Groningen. All patients gave
written informed consent [19]. The fourth Dutch study consisted
of observational, anonymised data from the large Asthma/COPD
service in the Netherlands. The privacy regulation of the study was
registered at the Dutch Data Protection Authority. According to
current Dutch legislation, neither informed consent nor approval
is required from a medical ethics committee for observational
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studies using anonymised data records [23]. The Greek study was
approved by the local medical ethics committee of the University
Hospital of Heraklion, Crete, Greece and all patients gave written
informed consent. The data is hosted at the department of
Thoracic Medicine in the University Hospital of Heraklion, Crete,
Greece [20]. The Swedish study was approved by the Regional
Ethical Review Board of Uppsala University, Uppsala, Sweden
(Dnr 2004:M-445, Dnr 2010/090 and Dnr 2012/252). Written
consent to use the information for future analysis was obtained for
all participating patients in 2005. The data is hosted in the
University of Uppsala, Sweden, at the department of Medical
Sciences: Respiratory Medicine & Allergology [21,22]. The first
and last author received all anonymised study datasets and
combined these in one dataset.
Large pharmaceutically sponsored COPD studies
(LPCS): We compared the patient characteristics of the
UNLOCK datasets with baseline data (if available) from six large
pharmaceutically sponsored COPD studies (hereafter called the
LPCS). These studies were published in the year 2000 or later: the
ISOLDE [9,24,25], TRISTAN [10], TORCH [11,26–29],
UPLIFT [12,30], ECLIPSE [13,31,32] and POET-COPD [14]
studies. In addition to five large trials, we decided to include the
ECLIPSE cohort study as well, because this is an important
observational study often cited in guidelines, especially with regard
to exacerbation frequency patterns.
Outcomes
Measurements: Measurements included age, gender, smok-
ing status, pack years, body mass index (BMI), lung function,
dyspnea, health-related quality of life, and exacerbations. For
smoking status, participants were categorized as never, ex- and
current smokers and, if available, the number of pack years was
calculated. BMI was calculated using [weight (kg)/(height (m)]2. In
all patients, spirometry was performed according to international
guidelines [8]. We grouped patients into GOLD stage categories
based on their post-bronchodilator FEV1% predicted as follows:
stage I corresponds to post-bronchodilator FEV1 $ 80%
predicted, stage II to post-bronchodilator FEV1 50% to , 80%
predicted, stage III corresponds to 30% to ,50% predicted, and
stage IV corresponds to # 30% predicted [8].
Definition of exacerbations: The definition of exacerbation
used in the UNLOCK, ISOLDE [9], TRISTAN [10], TORCH
[29] and ECLIPSE [32] studies was based on worsening of
symptoms and the decision by a patient’s clinician (or by study
personnel) to prescribe antibiotics or systemic corticosteroids,
alone or in combination. In the UPLIFT [30] and POET-COPD
[14] studies, an exacerbation was defined as an increase in or the
onset of more than one respiratory symptom (cough, sputum,
sputum purulence, wheezing, or dyspnea) lasting 3 days or more
and requiring treatment with an antibiotic or a systemic
corticosteroid. The mean exacerbation rate per person per year
was calculated and subsequently distributed per GOLD stage. We
also calculated the proportion of patients with at least one or two
exacerbations per year and compared these to baseline values of
the LPCS. If baseline data were missing, we contacted the authors
of the studies to request more information. When we received no
response or baseline data was not available, we used placebo-limb
data of the LPCS. Additionally, we used recent data of the GOLD
2013 guidelines [8], in which reference values of exacerbation
rates distributed per GOLD stage are stated.
Dyspnea and health-related quality of life question-
naires: Dyspnea was measured with the Medical Research
Council (MRC) dyspnea score [33]. We used the St Georges
Respiratory Questionnaire (SGRQ) which is designed to measure
health- related quality of life in patients with asthma and COPD
[34]. The Clinical COPD Questionnaire (CCQ) was also used: this
is a disease-specific 10-item questionnaire that calculates an overall
score and three domain scores: symptoms, functional state and
emotional state; patients are required to respond to each item on a
7-point scale with 0 representing the best possible score and 6
representing the worst possible score [35].
Data acquisition
Data on age, gender, lung function and GOLD stage were
available for all patients. The UNLOCK datasets had additional
data on the following subsets: current smoke status (98%), CCQ
(98%), number of exacerbations (79%), BMI (61%), MRC
dyspnea score (41%), SGRQ (32%) and pack years (25%). Mean
exacerbation rates in the UNLOCK study were calculated using
the number of exacerbations per patient in the year prior to
inclusion in the study, divided by the total number of patients in
the dataset, which provided data on the number of exacerbations.
Data analysis
All analyses were performed with SPSS software, version 21.
There were seven UNLOCK datasets. We calculated proportions
for frequencies, and means for continuous variables, for every
individual UNLOCK dataset. We used the means of the LPCS
reported in the original publications as a comparison. Using
independent sample t-tests, we tested the means of the seven (or
less, in case of subsets of data) UNLOCK studies to the means of
the six LPCS and reported mean differences, 95% confidence
intervals (CI) and p-values. We performed a sensitivity analysis on
primary care patients with GOLD stage II or above, in order to
compare whether patients enrolled in trials were similar to the
more severe patients in the primary care setting.
Furthermore, step-by-step we applied the inclusion criteria of
the trials [9,10,14,29,30,32] to the UNLOCK population and
calculated the proportion of patients eligible for inclusion.
Results
Baseline comparisons
Individual datasets: The UNLOCK datasets included a
total of 4286 patients diagnosed with COPD by a GP or
respiratory physician. After exclusion of patients with missing
lung function data (N= 524; 12%) and a ratio of FEV1/FVC of $
0.7 (N= 254; 7%), baseline characteristics of the remaining 3508
primary care COPD patients were compared with those of the
LPCS. Results of baseline characteristics of the individual
UNLOCK datasets and the LPCS are reported in Table 1.
Overall means of the UNLOCK and LPCS studies: The
overall means of the UNLOCK studies and the LPCS, including
the results of the independent sample t-tests, are reported in Table
2. Compared with the UNLOCK studies, the LPCS included a
statistically significant (mean difference (MD) -2.4; p = 0.03)
younger population with a higher proportion of males (MD
12.4; p = 0.1) and significant lower FEV1% predicted values (MD -
16.4; p,0.01) and lower FEV1/FVC values (MD -9.2; p,0.01).
There were large differences in GOLD distribution between the
UNLOCK studies and the LPCS. There was total absence of
GOLD I in the LPCS, whilst in the UNLOCK studies, mild and
moderate patients (GOLD I and II) comprised 74% of the total
COPD population. In the LPCS, the proportion of GOLD III
patients were more than doubled compared to the UNLOCK
population (44.5% versus 21%, MD 23.5; p,0.01). In addition,
primary care patients in the UNLOCK studies had significantly
better health-related quality of life (measured with the SGRQ)
The External Validity of Large COPD Studies
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compared with LPCS (MD 15.8; p = 0.01). In the TORCH and
ECLIPSE studies, the proportion of patients with an MRC score
.2 was measured, and in ECLIPSE the mean MRC scores were
reported as well. Overall mean MRC scores were similar in the
UNLOCK studies compared to ECLIPSE: 2.1 (0.8) and 2.7 (1.1),
respectively. However, overall 51.5% of the patients in the
ECLIPSE and TORCH studies had an MRC score .2, meaning
walking slower than most people on the level, whereas in the
UNLOCK studies this overall proportion was 32.3%, this mean
difference was statistically significant (p = 0.04).
Exacerbation data
Individual datasets: UNLOCK studies reporting exacerba-
tion data were compared with baseline data of the ISOLDE,
TRISTAN, TORCH, UPLIFT and ECLIPSE studies (Table 3).
There was heterogeneity between UNLOCK studies, with studies
from the Netherlands reporting lower exacerbation rates com-
pared to the UK study.
Overall means of the UNLOCK and LPCS studies: The
UNLOCK studies reported a lower mean exacerbation rate per
year compared to the LPCS (MD 0.3; p = 0.31), as well as a lower
proportion of patients with $ 1 (MD 15; p = 0.21) or $ 2
exacerbations (MD 8; p= 0.24); Table 4.
Exacerbation data distributed per GOLD stage
Exacerbation characteristics distributed per GOLD stage are
shown in Table 5 (individual datasets) and Table 6 (overall means).
When the severity of COPD increased (as measured with GOLD),
the proportion of COPD patients with at least one or two
exacerbations also increased, the exception being patients in
GOLD stage IV in UNLOCK patients, which had a lower
proportion compared to GOLD III on all these variables.
Furthermore, differences between GOLD stages in patients with
$ 1 or $ 2 exacerbation in the UNLOCK studies were not as
high as reported in the LPCS (Table 6).
Sensitivity analysis
We performed a sensitivity analysis on the UNLOCK datasets
including only patients with GOLD stage II or above, in order to
compare whether patients enrolled in the trials are similar to the
more severe patients in primary care. There was no difference
between the sensitivity analysis (Table S1) and Tables 2 and 4.
Selection for large COPD studies
The proportion of patients from primary care that would be
eligible to be included in the LPCS ranged from 17% (TRISTAN
trial) to 42% (ECLIPSE and UPLIFT study) (Table 7). The LPCS
inclusion criteria of at least one exacerbation in the preceding year
and an FEV1 of , 60% predicted, excluded the largest proportion
of primary care patients, as only 44% ($ 1 exacerbation in
previous year) and 39.3% (FEV1# 60% predicted) of the patients,
respectively, fulfilled these criteria.
Discussion
This is the first study using a large international COPD primary
care dataset from Europe to compare disease characteristics of
primary care COPD patients with disease characteristics of COPD
populations included in large pharmaceutically-sponsored COPD
studies (the LPCS). We demonstrated there were clear differences
in gender, age, distribution of GOLD stages, quality of life scores
and exacerbation characteristics between COPD patients seen in





UNLOCK – LPCS (95% CI) p-value
Patients (N) 3508 23860
Age, years 66.1 (2.3) 63.7 (0.9) –2.4 (–4.6 — –0.3) 0.03*
Male, % 60.9 (16.7) 73.3 (4.1) 12.4 (–3.1—27.9) 0.1
Current smokers, % 42.9 (9.5) 40.7 (8.6) –2.2 (–13.2—8.8) 0.67
Pack years 43.6 (13.5) 44.9 (4.03) 1.3 (–15.2—17.8) 0.84
BMI, kg/m2 26.3 (0.5) 25.6 (0.9) –0.7 (–2 —0.6) 0.23
Postbronchodilator FEV1, %
predicted
63.8 (8.7) 47.4 (2.4) –16.4 (–24—–8.2) ,0.01*
FEV1:FVC, % 55.7 (0.7) 46.5 (4.0) –9.2 (–14.1 —–4.2) ,0.01*
GOLD distribution
Mild GOLD I 20.7 (13.2) - - -
Moderate GOLD II 53.3 (6.2) 45 (6.3) –8.3 (–16.6—0.1) 0.05
Severe GOLD III 21 (10.1) 44.5 (3.1) 23.5 (13.9—33.1) ,0.01*
Very severe GOLD IV 5.8 (5.2) 11.5 (3.5) 5.7 (–0.71—12) 0.08
Patient-reported outcomes
SGRQ 32.6 (6.2) 48.4 (1.9) 15.8 (6.3—25.4) 0.01*
CCQ (mean) 1.6 (0.3) - - -
MRC (mean) 2.1 (0.8) 2.7 (1.1) 0.6 (–1.5—2.7) 0.5
MRC score . 2 (%) 32.3 (17) 51.5 (2.1) 19.2 (1.3—37) 0.04*
Data are overall mean values (SD), in which every dataset or study contributed equally to the overall means. ‘‘-‘‘ indicates data not available. 95% CI: 95% confidence
interval. Abbreviations: BMI: body mass index; FEV1: forced expiratory volume in 1 second; GOLD: Global initiative for chronic Obstructive Lung Disease; SGRQ: St
Georges Respiratory Questionnaire; CCQ: Clinical COPD Questionnaire; MRC: Medical Research Counsil.
doi:10.1371/journal.pone.0090145.t002
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primary care and included in the LPCS. As a result, the majority
(58–83%) of COPD patients in primary care would not serve as a
candidate for inclusion in these LPCS.
The present study provides insight into the disease character-
istics of COPD in primary care, including the milder affected
patients. According to GOLD guidelines [8], prevalence data on
exacerbation rates in GOLD I were currently lacking in literature,
whereas data on GOLD II-IV stages were based on selected
COPD populations of the LPCS and were not validated in
primary care. In the ECLIPSE study, Hurst et al. showed that the
best predictor of exacerbations (across all GOLD stages) was an
exacerbation history [13]. Interestingly, we determined that 12%
of GOLD I patients in primary care were frequent exacerbators
($ 2 exacerbations per year). Furthermore, we demonstrated 34%
of GOLD I patients exacerbated at least once yearly. Since
moderate COPD is more prevalent than very severe COPD, the
overall burden of exacerbations in terms of FEV1 decline, and the
costs may be greater with milder disease [13]. On the other hand,
physicians should be aware that the majority of mild COPD
patients are often symptom free and often remain undiagnosed, as
earlier demonstrated in the international BOLD and PLATINO
studies [36,37]. It could be important to intervene at an early stage
of the disease [38], but pharmacological intervention should in
general be reserved for symptomatic patients or frequent
exacerbators, whilst asymptomatic GOLD I patients can be
offered non-pharmacological strategies, such as smoking cessation,
aimed at preventing further worsening of the disease.
Interestingly, we demonstrated the majority of COPD patients
in primary care would not serve as a candidate for inclusion in
large pharmaceutically sponsored studies. As a result, primary care
physicians are left to treat patients based on results derived from
trials that their patients would not have been eligible to join. The
economic impact of this low external validity potentially leads to
considerable avoidable costs. Over-prescribing of inhaled steroids
in primary care is described in various countries [16,39–42]. One
recent UK primary care study concluded 38% of patients were
over-treated regarding their GOLD stage, with considerable
potential for harm and a mean extra per patient cost of
£553.56/year [41]. This is in line with results of a Spanish
primary care study, in which 18.2% of patients received inhalation
therapy not meeting criteria for its use as recommended in
guidelines, which was associated with lower physical health status
and higher annual costs [42]. The revised GOLD 2013 guidelines
acknowledge the lack of evidence concerning anti-inflammatory
and bronchodilator medications in patients with GOLD stage I
and II [8]. Subsequent post-hoc analysis of the TORCH trial
concluded that a combination of salmeterol and fluticasone
propionate reduced exacerbations and FEV1 decline in patients
with a FEV1 of 50–60% predicted [28]. However, that study was
not specifically powered to show differences between GOLD
stages and, as inclusion was restricted to FEV1 of 60%, many
GOLD II patients were not included. Subgroup analysis of
UPLIFT showed promising results of tiotropium in GOLD II
patients on FEV1 decline [12], but inclusion was limited to patients
with FEV1,70%, leading to incomplete representation of GOLD
II. More research is needed to determine the effect of inhalation
therapies in mild to moderate COPD patients, and we strongly
encourage guideline makers to base their recommendations on
primary care studies as well.



















Patients (N) 86 375 1665 902 370 * 361 * 6112 5992 2138
Mean exacerbation
rate p/year
1.05 (1.3) 1.32 (1.6) 0.72 (1.1) 0.54 (1.19) 1.90 (2.63)* 1.30 * 1.0 (1.3) 0.85 (0.02)* 0.9 (1.2)
$1 in preceding
year, % (n/N)
55 (47/85) 59 (222/374) 43 (713/1661) 27 (174/636) 63* - 57 68* 47
$2 in preceding
year, % (n,N)
29 (25/85) 33 (124/374) 19 (312/1661) 11 (72/636) - - 32 - 29
Data are baseline data and mean values (SD), unless stated otherwise. *indicates data from placebo group; ‘‘-‘‘ indicates data not available.
doi:10.1371/journal.pone.0090145.t003
Table 4. Mean exacerbation data of the UNLOCK studies, compared with mean exacerbation data of the large pharmaceutically




Mean difference between UNLOCK-LPCS
(95% CI) p-value
Patients (N) 3028 14973
Mean exacerbation rate p/year 0.9 (3.5) 1.2 (0.4) 0.3 (–0.3—0.9) 0.31
Mean % of patients with $1
exacerbation in preceding year
44 (14.4) 59 (9) 15 (–12—42) 0.21
Mean % of patients with $2 in
preceding year
22 (10) 30 (2.1) 8 (–9—25) 0.24
Data are overall mean values (SD), in which every dataset or study contributed equally to the overall means. 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0090145.t004
The External Validity of Large COPD Studies





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The External Validity of Large COPD Studies
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e90145
Our population based data reflect the recent tendency towards
an increasing prevalence of COPD in women, drawing a different
picture of the current COPD patient than the one represented in
the LPCS. In fact, underrepresentation of women in large medical
trials is not uncommon, resulting in a call in Nature for other
journals, funding agencies and researchers to give women parity
with men [43]. As the prevalence of COPD in women is rising, we
advise future trialists to include not only milder COPD patients,
but also more female participants, in order to study whether
biological differences affect the way women respond to medica-
tions and therapeutic strategies.
Two studies published in 2005 and 2007 evaluated the external
validity in COPD patients using smaller datasets [5,6]. Although
their results are in line with our conclusions, there are some






UNLOCK-LPCS (95% CI) p-value
Patients (N) 3028 14973
$1 exacerbations p/year distributed per GOLD
stage
GOLD I, % (n/N) 34.3 (11.7) - -
GOLD II, % (n/N) 43 (14.1) 58.3 (17) 15.3 (–18.6—49.2) 0.28
GOLD III, % (n/N) 58.3 (17.5) 69 (16.1) 10.7 (–22.8—44.3) 0.33
GOLD IV, % (n/N) 54.3 (14.1) 71.7 (11.2) 17.4 (–7.3—42.1) 0.13
$2 exacerbations p/y distributed per GOLD stage
GOLD I, % (n/N) 12 (2.0) - -
GOLD II, % (n/N) 21.3 (9.6) 22 15.3 (–18.6—49.2) 0.28
GOLD III, % (n/N) 32 (13.9) 33 10.7 (–22.8—44.3) 0.33
GOLD IV, % (n/N) 27.8 (9.7) 47 17.4 (–7.3—42.1) 0.13
Exacerbation rate distributed per GOLD stage
GOLD I 0.55 (1) - -
GOLD II 0.81 (0.3) 0.84 (1) 0.03 (–0.5—0.5) 0.85
GOLD III 1.25 (0.4) 1.27 (0.4) 0.02 (–0.7—0.7) 0.95
GOLD IV 1.13 (0.5) 1.55 (0.4) 0.42 (–0.32—1.16) 0.22
Data are overall mean values (SD), in which every dataset or study contributed equally to the overall means. ‘‘-‘‘ indicates data not available. 95%CI : 95% confidence
interval. Abbreviations: GOLD: Global initiative for chronic Obstructive Lung Disease.
doi:10.1371/journal.pone.0090145.t006
Table 7. Percentage of patients remaining after introduction of different selection criteria used in six large COPD studies.
Age 40–75 years 40–80 years $ 40 years 40–75 years $ 40 years
% of patients in primary care 77.2 89.9 99.7 77.2 99.7
FER # 70% # 70% # 70% # 70% # 70% # 70%
% of patients in primary care 93.2 93.2 93.2 93.2 93.2 93.2
FEV1 , 85% 25–70% , 60% # 70% , 80% # 70%
% of patients in primary care 83.4 57.9 39.3 59.3 76.5 59.3
Reversibility # 10% # 10% # 10%
% of patients in primary care 78.4 78.4 78.4
Smoking status Current/ex-smoker Current/ex-smokerCurrent/ex-smokerCurrent/ex-smoker
% of patients in primary care 82.3 82.3 82.3 82.3
Pack years $ 10 pack years $ 10 pack years $ 10 pack years $ 10 pack years $ 10 pack years
% of patients in primary care 93 93 93 93 93





Total % of patients in
primary care
39 17 20 42 42 23
doi:10.1371/journal.pone.0090145.t007
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important differences. Herland et al. used a population of mixed
obstructive lung disease and concluded that only 17% of these
patients were eligible for inclusion in a typical COPD RCT;
included COPD patients (n = 366) were not classified according to
GOLD criteria, but were graded using a 10-cm free-graded visual
analogue scale which had to differentiate between asthma, COPD
and mixed obstructive lung disease [5]. In the study of Travers et
al., only 0–9% of COPD patients were eligible for inclusion based
on the very strict criteria of trials conducted between 1994 and
2003 [6]. It is likely that in more recent years less strict inclusion
criteria were used for participation in a trial.
This study has several limitations that should be addressed.
First, the current analysis of primary care COPD patients was
restricted to seven datasets from four different countries in Europe;
as a consequence, our data will probably not be representative for
all primary care populations worldwide. Second, as there are
differences in COPD patients between countries, there was
considerable heterogeneity between populations in the different
databases, with for example patients from the UK having more
exacerbations per year and worse quality of life scores compared
to Dutch patients. Although it would be interesting to further
evaluate these differences between countries, the present study
does not allow drawing firm conclusions about these differences.
Perhaps this study will provide an useful starting point for further
validation in a larger, more diverse population of COPD patients
across a multitude of different countries. Third, all individual
datasets included baseline data collected in different designs of
studies ranging from pragmatic clinical trials to real-life cohort
studies. Irrespective of these varying designs, all studies had few or
no exclusion criteria, making the dataset a reasonably represen-
tative sample of primary care populations in these countries.
Fourth, as data were accessed retrospectively from different types
of studies, some data were available on subsets of outcomes. As a
result of heterogeneity and a low number of studies used for
independent sample t-tests, on some outcomes mean differences
were large and represented important findings, whilst showing no
statistically significance. Therefore, the statistical tests performed
in this study should be interpreted with caution. However, our aim
was to provide illustrative findings rather than to be conclusive,
and we assumed that our findings are based on a representative
sample of primary care patients. In addition, we feel we provided
an overall dataset large enough to make reliable comparisons with
the LPCS, as we evaluated a similar number of included patients.
Finally, another limitation is that, for comparison purposes, the
present study compared primary care data to six LPCS. Although
many other large COPD studies have been published over the
years, we chose to evaluate the studies most frequently referred to
in the guidelines, and published in the last decade.
Conclusion
This study provides an informative insight into COPD patient
characteristics in primary care. Overall, compared to primary care
patients, patients in large pharmaceutically sponsored trials were
younger, predominantly male with worse lung function and worse
quality of life scores. Our findings add to the literature, as we
revealed hitherto unknown GOLD I exacerbation characteristics,
showing 34% of mild patients had $1 exacerbations per year and
12% had $ 2 exacerbations per year. Additionally, the majority of
patients seen in primary care would not be eligible to be included a
large pharmaceutically sponsored trial. Therefore, more research
is needed to determine the effect of pharmacological treatment in
mild to moderate patients. Furthermore, we encourage future
guideline makers to involve primary care populations in their
recommendations as well.
Supporting Information
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